Important updates on COVID-19 therapeutics for treatment and prevention
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields



Publication Date Range:


Document Data


Document Type:






Clear All

Query Builder

Query box

Clear All

For additional assistance using the Custom Query please check out our Help Page



Up-to-date Information

Up-to-Date Info: To find the latest CDC information on this topic go to:

Important updates on COVID-19 therapeutics for treatment and prevention

Filetype[PDF-222.13 KB]

  • English

  • Details:

    • Description:
      Distributed via the CDC Health Alert Network

      December 20, 2022, 5:45 PM ET


      The Centers for Disease Control and Prevention (CDC) is issuing this Health Alert Network (HAN) Health Update to supplement the CDC HAN Health Advisories issued on April 25, 2022 and May 24, 2022 to emphasize to healthcare providers, public health departments, and the public that the majority of Omicron sublineages circulating in the United States have reduced susceptibility to the monoclonal antibody, bebtelovimab and the monoclonal antibody combination, cilgavimab and tixagevimab (EvusheldTM).

      Because of this reduced susceptibility, on November 30, 2022, the Food and Drug Administration (FDA) announced that the use of bebtelovimab is not currently authorized for use for patients with COVID-19. The monoclonal antibody combination, cilgavimab and tixagevimab (EvusheldTM), currently recommended for pre-exposure prophylaxis, remains authorized for persons with moderate to severe immunosuppression and for those whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s). However, providers should be aware and communicate to patients that its effectiveness may be increasingly limited against circulating Omicron sublineages.

      Antiviral therapeutics for the treatment of COVID-19, ritonavir-boosted nirmatrelvir (PaxlovidTM), remdesivir (Veklury®), and molnupiravir (LagevrioTM), retain activity against currently circulating Omicron sublineages. These medications can prevent severe disease, hospitalization, and death and are widely available but have been underused.

      This HAN Health Update provides health care professionals, public health officials, and the public with guidance on improving use of therapeutics for treatment of COVID-19 and strategies to prevent serious outcomes of COVID-19.

    • Series:
    • Document Type:
    • Main Document Checksum:
    • File Type:

    Supporting Files

    More +

    You May Also Like

    Checkout today's featured content at